IL128610A - Cryptophycin compound and its use as a medicament for treating neoplasm - Google Patents

Cryptophycin compound and its use as a medicament for treating neoplasm

Info

Publication number
IL128610A
IL128610A IL12861097A IL12861097A IL128610A IL 128610 A IL128610 A IL 128610A IL 12861097 A IL12861097 A IL 12861097A IL 12861097 A IL12861097 A IL 12861097A IL 128610 A IL128610 A IL 128610A
Authority
IL
Israel
Prior art keywords
cryptophycin
group
mmol
alkyl
boc
Prior art date
Application number
IL12861097A
Other languages
English (en)
Other versions
IL128610A0 (en
Original Assignee
Lilly Co Eli
Univ Hawaii
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Univ Hawaii, Univ Wayne State filed Critical Lilly Co Eli
Publication of IL128610A0 publication Critical patent/IL128610A0/xx
Publication of IL128610A publication Critical patent/IL128610A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12861097A 1996-08-30 1997-08-29 Cryptophycin compound and its use as a medicament for treating neoplasm IL128610A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2581696P 1996-08-30 1996-08-30
US3911397P 1997-02-26 1997-02-26
US3953097P 1997-03-03 1997-03-03
US4002997P 1997-03-04 1997-03-04
PCT/US1997/015240 WO1998008505A1 (en) 1996-08-30 1997-08-29 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
IL128610A0 IL128610A0 (en) 2001-01-28
IL128610A true IL128610A (en) 2004-07-25

Family

ID=27487441

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12861097A IL128610A (en) 1996-08-30 1997-08-29 Cryptophycin compound and its use as a medicament for treating neoplasm

Country Status (20)

Country Link
EP (1) EP0934065B1 (de)
JP (1) JP4364944B2 (de)
CN (1) CN100356916C (de)
AT (1) ATE328592T1 (de)
AU (1) AU722492B2 (de)
BR (1) BR9711986A (de)
CA (1) CA2264063C (de)
CZ (1) CZ64599A3 (de)
DE (1) DE69736067T9 (de)
DK (1) DK0934065T3 (de)
EA (1) EA001913B1 (de)
ES (1) ES2267149T3 (de)
HK (1) HK1025036A1 (de)
IL (1) IL128610A (de)
NO (1) NO314454B1 (de)
PT (1) PT934065E (de)
SI (1) SI0934065T1 (de)
TR (1) TR199901104T2 (de)
WO (1) WO1998008505A1 (de)
YU (1) YU10899A (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
JP2001506970A (ja) * 1996-09-06 2001-05-29 イーライ・リリー・アンド・カンパニー 方法及び新規な中間体
EP0956295A1 (de) * 1996-09-06 1999-11-17 Eli Lilly And Company Herstellungsverfahren für arzneistoffe
AU6338698A (en) * 1997-02-26 1998-09-18 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
NZ336918A (en) * 1997-02-26 2001-11-30 Lilly Co Eli Selective epoxidation process for preparing pharmaceutical compounds comprising Cryptophycin 52
EP0870501A1 (de) * 1997-04-11 1998-10-14 Eli Lilly And Company Verwendung von specifischen Cryptophycin Derivaten zur Herstellung eines Medikaments für die Behandlung von Pilzinfektionen
EP0870506A1 (de) * 1997-04-11 1998-10-14 Eli Lilly And Company Zusammentsetzungen enthaltend ein Cryptophycin Derivat in Kombination mit einem synchronisierten Wirkstoff oder Aktivierungsmittel zur Behandlung von Krebs
EP0870510A3 (de) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistische Zusammensetzung enthaltend Cryptophycinderivate und synergistische mikrotubuli Mitteln
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
US6372936B1 (en) * 1999-06-09 2002-04-16 Eli Lilly And Company Optical resolution of aminoisobobutyric acid
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6747021B2 (en) 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
ES2337134T3 (es) 2002-03-12 2010-04-21 Bristol-Myers Squibb Company Derivados de c3-ciano-epotilona.
KR20080091829A (ko) * 2006-02-09 2008-10-14 엔존 파마슈티컬즈, 인코포레이티드 유방암, 대장암, 췌장암, 난소암 및 폐암 치료용 7―에틸―10―히드록시캄포테신의 다분지형 고분자 접합체
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
WO2012052843A1 (en) * 2010-10-22 2012-04-26 Universite De Strasbourg Pochoxime conjugates useful for the treatment of hsp90 related pathologies
IT201600108581A1 (it) * 2016-10-27 2018-04-27 Navid Sobhani NUOVE E PIU' POTENTI MOLECOLE PER IL TRATTAMENTO E LA DIAGNOSI DI TUMORI NEUROENDOCRINI (NETs) E DELLE CELLULE STAMINALI DEI NETs
CN110831633A (zh) * 2017-05-10 2020-02-21 赛诺菲 可用于治疗的肽类接头和念珠藻素缀合物及其制备
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins
US5952298A (en) * 1993-12-21 1999-09-14 The University Of Hawaii Cryptophycins
MD2196B2 (ro) * 1995-03-07 2003-06-30 Юнивэсити Эв Хауайи Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
JP2000501067A (ja) * 1995-08-30 2000-02-02 イーライ・リリー・アンド・カンパニー 医薬化合物
CA2241086A1 (en) * 1995-12-22 1997-07-03 University Of Hawai'i Pharmaceutical compounds
DE69704731D1 (de) * 1996-02-27 2001-06-13 Lilly Co Eli Cryptophycinderivate und ihre Verwendung als antimikrotubuli Mittel

Also Published As

Publication number Publication date
PT934065E (pt) 2006-10-31
BR9711986A (pt) 1999-08-24
CA2264063A1 (en) 1998-03-05
ATE328592T1 (de) 2006-06-15
WO1998008505A1 (en) 1998-03-05
YU10899A (sh) 2002-03-18
EP0934065B1 (de) 2006-06-07
CA2264063C (en) 2007-03-13
SI0934065T1 (sl) 2007-02-28
DE69736067D1 (en) 2006-07-20
HK1025036A1 (en) 2000-11-03
JP2002514175A (ja) 2002-05-14
WO1998008505A8 (en) 1999-08-12
NO990833D0 (no) 1999-02-22
NO990833L (no) 1999-04-26
IL128610A0 (en) 2001-01-28
EA199900246A1 (ru) 1999-10-28
DE69736067T9 (de) 2007-10-31
ES2267149T3 (es) 2007-03-01
CN1233957A (zh) 1999-11-03
JP4364944B2 (ja) 2009-11-18
DE69736067T2 (de) 2007-05-10
EP0934065A4 (de) 2000-10-11
DK0934065T3 (da) 2006-10-09
NO314454B1 (no) 2003-03-24
CN100356916C (zh) 2007-12-26
EP0934065A1 (de) 1999-08-11
AU722492B2 (en) 2000-08-03
CZ64599A3 (cs) 1999-10-13
AU4170197A (en) 1998-03-19
TR199901104T2 (xx) 1999-07-21
EA001913B1 (ru) 2001-10-22

Similar Documents

Publication Publication Date Title
US6680311B1 (en) Cryptophycin compounds
EP0934065B1 (de) Neue cryptophycin-derivate als antineoplastika
WO1998002426A1 (fr) Derives de taxane et medicaments les contenant
JP2023549547A (ja) 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとして使用するための1,3,4-オキサジアゾール環を含有する大環状化合物
LV13120B (en) Delta 12, 13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
CA2230540A1 (en) Pharmaceutical compounds
BG63289B1 (bg) Нови криптофицини и метод за получаването им
JPH10502077A (ja) 7−エーテル−タキソールアナログ、抗新生生物用途およびそれを含有する医薬組成物
CA2263420A1 (en) Pharmaceutical compounds
BR112020019963A2 (pt) Composto com atividade anticâncer
JPWO2007049575A1 (ja) アゼチジン環構造を有するタキサン化合物
WO1998008829A1 (en) Pharmaceutical compounds
US20020128185A1 (en) Pharmaceutical compounds
TW533206B (en) A novel cryptophycin compound and its pharmaceutical composition
MXPA99001825A (en) Pharmaceutical compounds
KR100505779B1 (ko) 제약 화합물
TW202233634A (zh) 囊腫纖維化跨膜傳導調節蛋白之調節劑
MXPA98001604A (en) Farmaceuti compounds
OA21166A (en) Modulators of cystic fibrosis transmembrane conductance regulator.
KR100499809B1 (ko) 내성균에 항생작용을 갖는 아릴카보닐아제티딘이 치환된카바페넴 유도체 및 이의 제조방법
JP3784945B2 (ja) タキソール誘導体
JP2004203809A (ja) 新規ビフェニル誘導体
MXPA05001176A (es) Sintesis total de miriaporonas.
TW200842126A (en) Taxane compound having azetidine ring structure

Legal Events

Date Code Title Description
ERR Corrigendum

Free format text: JOURNAL 5/04 P. 1821 PATENT APPLICATION NO. 128610 CORRECT NAME OF APPLICANT TO- THE UNIVERSITY OF HAWAII AND WAYNE STATE UNIVERSITY

FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired